Figure 6. The comparison of the predictive power among 21-gene recurrence score (Gene21), 70-gene prognosis signature (Gene70), the tamoxifen efficacy-related long noncoding RNA signature (TLS), the integrated model of Gene21 with TLS and the integrated model of Gene70 with TLS in different subgroups of all patients. The receiver operating characteristic (ROC) of Gene21, Gene70, TLS, the integrated model of Gene21 with TLS and the integrated model of Gene70 with TLS were plotted and corresponding area under the ROC curve (AUC) was calculated in total tamoxifen treated breast cancer patients (A), all lymph node-negative patients (B), all lymph node-positive patients (C), all luminal A patients (D), and all luminal B patients (E).